Novartis Bioventures Ltd 4
4 · Galera Therapeutics, Inc. · Filed Nov 12, 2019
Insider Transaction Report
Form 4
Novartis Bioventures Ltd
10% Owner
Transactions
- Conversion
Common Stock
2019-11-12+3,293,067→ 3,293,067 total(indirect: See footnote) - Purchase
Common Stock
2019-11-12$12.00/sh+250,000$3,000,000→ 3,543,067 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2019-11-12−9,000,000→ 0 total(indirect: See footnote)→ Common Stock (1,779,864 underlying) - Conversion
Series B Preferred Stock
2019-11-12−7,200,000→ 0 total(indirect: See footnote)→ Common Stock (1,423,891 underlying) - Conversion
Series C Preferred Stock
2019-11-12−451,609→ 0 total(indirect: See footnote)→ Common Stock (89,311 underlying)
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.
- [F2]Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.